Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1998-4-20
|
pubmed:abstractText |
Abs are able to induce inflammatory antitumor responses by recruiting IgG Fc receptor (FcgammaR)-bearing cytotoxic effector cells. We recently described the capacity of the high affinity FcgammaRI (CD64) to trigger cytotoxic activity of neutrophils (PMN) during granulocyte CSF (G-CSF) treatment. To take advantage of FcgammaRI as a cytotoxic trigger molecule on PMN, two Ab constructs were prepared. We show that a chimeric human IgG1 Ab (Ch520C9) and an anti-FcgammaRI bispecific Ab (BsAb; 22x520C9), both directed to the proto-oncogene product HER-2/neu, interact with FcgammaRI. In addition, both Ab constructs mediate enhanced lysis of HER-2/neu-expressing tumor cells by G-CSF-primed PMN. However, engagement of FcgammaRI by Ch520C9 was inhibited by human serum IgG, thereby abrogating the enhanced Ch520C9-mediated cytotoxicity. BsAb 22x520C9, which binds FcgammaRI outside the ligand binding domain, effectively recruits the cytotoxic potential of FcgammaRI on G-CSF-primed PMN regardless of the presence of human serum. These results indicate that under physiologic conditions, serum IgG impairs activation of FcgammaRI-mediated cytotoxicity by conventional antitumor Abs. The IgG blockade can be circumvented with anti-FcgammaRI BsAbs. Using human FcgammaRI transgenic mice we demonstrate that BsAb 22x520C9 is able to engage FcgammaRI in vivo. BsAb 22x520C9 injected i.v. was readily detected on circulating PMN of G-CSF-treated transgenic animals. In addition, we showed that PMN remain "armed" with BsAb 22x520C9 during migration to inflammatory sites, and that after isolation such PMN specifically lyse HER-2/neu-expressing tumor cells. These results point to the possibility of targeting anti-FcgammaRI BsAbs to G-CSF-primed PMN in vivo, endowing them with specific anti-tumor activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bispecific,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgG,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-1767
|
pubmed:author |
pubmed-author:CapelP JPJ,
pubmed-author:DechantMM,
pubmed-author:GlennieM JMJ,
pubmed-author:HeijnenI AIA,
pubmed-author:KelerTT,
pubmed-author:RijksL JLJ,
pubmed-author:SchierGG,
pubmed-author:StockmeyerBB,
pubmed-author:TuttA LAL,
pubmed-author:ValeriusTT,
pubmed-author:van OjikH HHH,
pubmed-author:van RoyenE AEA,
pubmed-author:van de WinkelJ GJG
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
159
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5629-39
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:9548506-Animals,
pubmed-meshheading:9548506-Antibodies, Bispecific,
pubmed-meshheading:9548506-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:9548506-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9548506-Humans,
pubmed-meshheading:9548506-Mice,
pubmed-meshheading:9548506-Mice, Transgenic,
pubmed-meshheading:9548506-Neutrophils,
pubmed-meshheading:9548506-Receptor, erbB-2,
pubmed-meshheading:9548506-Receptors, IgG,
pubmed-meshheading:9548506-Recombinant Proteins,
pubmed-meshheading:9548506-Tumor Cells, Cultured
|
pubmed:year |
1997
|
pubmed:articleTitle |
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
|
pubmed:affiliation |
Department of Immunology, University Hospital Utrecht, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|